Accessibility links

Breaking News

Vaccine Eliminates Allergy Symptoms

U.S. researchers have developed a vaccine that offers protection against a common allergy trigger in the United States known as ragweed. Scientists say the development has the potential to guard against any number of inflammatory diseases.

Ragweed, which causes hay fever, is the number-one cause of allergic symptoms during the autumn season in the United States.

Hay fever produces sneezing, an itchy, runny nose and watery eyes. The problem is worst in the eastern and midwestern United States. The symptoms are triggered by pollen from the yellow flowering ragweed.

The allergic sufferer, according to expert Peter Creticos, produces too much of an antibody called I.g.E. This triggers an excessive immune response to otherwise harmless substances such as pollen.

"The question is, 'Can you turn off that I.g.E.-mediated allergic process?' With traditional immuno-therapy, you can accomplish that. But it takes years and years," he said.

That would be an average of four to five years of going to an allergist for weekly injections to become fully immune to the ravages of ragweed pollen.

But Creticos, an associate professor of medicine at Johns Hopkins University in the eastern U.S. state of Maryland, and colleagues have conducted trials of an experimental vaccine that achieves the same level of protection in just six injections.

In a study published in the New England Journal of Medicine, a team led by Creticos reports the vaccine virtually eliminated ragweed symptoms in 14 severely affected individuals between the ages of 23 and 60.

The drug, administered in six weekly shots before the 2001 ragweed season, protected the study participants that year and through the 2002 ragweed season.

Investigators do not know yet whether the vaccine will offer protection beyond two years, but they think it will.

The vaccine was developed by Dynavax Technologies of Berkeley, California, which funded the clinical trials.

Co-author David Broide of the University of California in San Diego says the drug acts as a decoy to deceive the immune system of allergy sufferers.

"Bacteria activate a protective-host immune response. And we have taken advantage of this by tagging the allergen with this little piece of bacterial DNA, which is not infectious, and which results in the immune system being fooled into thinking that they are seeing a bacteria instead of an allergen," he said. "And they do not bring up the allergic immune response."

Broide says the vaccine will not be available for at least another two years.

In time, researchers hope to use the DNA technology to create vaccines against grass pollen, cat dander and dust, as well as more serious diseases such as hepatitis.